IN2013MU02611A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02611A
IN2013MU02611A IN2611MU2013A IN2013MU02611A IN 2013MU02611 A IN2013MU02611 A IN 2013MU02611A IN 2611MU2013 A IN2611MU2013 A IN 2611MU2013A IN 2013MU02611 A IN2013MU02611 A IN 2013MU02611A
Authority
IN
India
Prior art keywords
compounds
diseases
inhibitors
janus kinase
present
Prior art date
Application number
Inventor
Ranjit C Desai
Jigar Desai
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/910,028 priority Critical patent/US9556148B2/en
Priority to PCT/IN2014/000515 priority patent/WO2015019365A1/en
Priority to PL14793899T priority patent/PL3030561T3/en
Priority to JP2016517296A priority patent/JP2016525071A/en
Priority to ES14793899.7T priority patent/ES2618072T3/en
Priority to HUE14793899A priority patent/HUE033448T2/en
Priority to TW103126910A priority patent/TWI562990B/en
Priority to EP14793899.7A priority patent/EP3030561B1/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN2611MU2013 priority patent/IN2013MU02611A/en
Priority to PT147938997T priority patent/PT3030561T/en
Priority to KR1020167005187A priority patent/KR101665301B1/en
Priority to CN201480054915.9A priority patent/CN105612154A/en
Priority to DK14793899.7T priority patent/DK3030561T3/en
Priority to ARP140102982A priority patent/AR097282A1/en
Publication of IN2013MU02611A publication Critical patent/IN2013MU02611A/en
Priority to HK16110100.8A priority patent/HK1222386A1/en
Priority to HRP20170277TT priority patent/HRP20170277T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Abstract

ABSTRACT “NOVEL COMPOUNDS AS INHIBITORS OF JANUS KINASE” The present invention relates to compounds of general formula (1) that are inhibitors of Janus Kinase (JAK), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound of the invention inhibits JAK1 and/or JAK2 and/or JAK3 sub families. The present invention also provides methods for the production of the compounds of the invention, pharmaceutical compositions comprising the compounds of the invention, their tautomeric forms, and their pharmaceutically acceptable salts.
IN2611MU2013 2013-08-07 2014-08-06 IN2013MU02611A (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IN2611MU2013 IN2013MU02611A (en) 2013-08-07 2014-08-06
PCT/IN2014/000515 WO2015019365A1 (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
PT147938997T PT3030561T (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
ES14793899.7T ES2618072T3 (en) 2013-08-07 2014-08-06 N-Cyanomethylamides as Janus kinase inhibitors
HUE14793899A HUE033448T2 (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
TW103126910A TWI562990B (en) 2013-08-07 2014-08-06 Novel compounds as inhibitors of janus kinase
EP14793899.7A EP3030561B1 (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
US14/910,028 US9556148B2 (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
PL14793899T PL3030561T3 (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
JP2016517296A JP2016525071A (en) 2013-08-07 2014-08-06 N-cyanomethylamide as an inhibitor of Janus kinase
KR1020167005187A KR101665301B1 (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
CN201480054915.9A CN105612154A (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of Janus Kinase
DK14793899.7T DK3030561T3 (en) 2013-08-07 2014-08-06 N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE
ARP140102982A AR097282A1 (en) 2013-08-07 2014-08-07 COMPOUNDS AS INHIBITORS OF THE JANUS QUINASA
HK16110100.8A HK1222386A1 (en) 2013-08-07 2016-08-24 N-cyanomethylamides as inhibitors of janus kinase n-
HRP20170277TT HRP20170277T1 (en) 2013-08-07 2017-02-21 N-cyanomethylamides as inhibitors of janus kinase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2611MU2013 IN2013MU02611A (en) 2013-08-07 2014-08-06

Publications (1)

Publication Number Publication Date
IN2013MU02611A true IN2013MU02611A (en) 2015-06-12

Family

ID=54199342

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2611MU2013 IN2013MU02611A (en) 2013-08-07 2014-08-06

Country Status (16)

Country Link
US (1) US9556148B2 (en)
EP (1) EP3030561B1 (en)
JP (1) JP2016525071A (en)
KR (1) KR101665301B1 (en)
CN (1) CN105612154A (en)
AR (1) AR097282A1 (en)
DK (1) DK3030561T3 (en)
ES (1) ES2618072T3 (en)
HK (1) HK1222386A1 (en)
HR (1) HRP20170277T1 (en)
HU (1) HUE033448T2 (en)
IN (1) IN2013MU02611A (en)
PL (1) PL3030561T3 (en)
PT (1) PT3030561T (en)
TW (1) TWI562990B (en)
WO (1) WO2015019365A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801910A (en) * 2016-06-01 2016-07-27 扬州兰都塑料科技有限公司 Flame-retardant auxiliary for power cables
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1286302B1 (en) 1996-04-10 1998-07-08 Rotta Research Lab CHINAZOLINE-4-AMINO-2- (PIPERIDINO-1-IL-4-SUBSTITUTED) WITH ANTI-HYPERTENSIVE ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND USE
ATE303987T1 (en) 1999-05-24 2005-09-15 Mitsubishi Pharma Corp PHENOXYPROPYLAMIN DERIVATIVES
GB0012240D0 (en) 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
IL155443A0 (en) 2000-11-02 2003-11-23 Wyeth Corp 1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
TW200407127A (en) 2002-08-21 2004-05-16 Astrazeneca Ab Chemical compounds
DE10250708A1 (en) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
ITMI20040954A1 (en) 2004-05-12 2004-08-12 Univ Degli Studi Milano DERIVATIVES OF 3,6-DIAZABICICLO 3.1.I. HEPTANE WITH ANALGESIC ACTIVITY
ES2427046T3 (en) 2004-06-21 2013-10-28 Galapagos N.V. Methods and means for the treatment of osteoarthritis
JP4624315B2 (en) 2005-12-20 2011-02-02 株式会社リヒトラブ Binding tool
EP1979329A2 (en) 2006-01-30 2008-10-15 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use
EP2099454A4 (en) 2006-11-17 2010-11-10 Abbott Lab Aminopyrrolidines as chemokine receptor antagonists
PL2152701T3 (en) * 2007-03-12 2016-10-31 Phenyl amino pyrimidine compounds and uses thereof
EP2152079A4 (en) 2007-06-04 2011-03-09 Avila Therapeutics Inc Heterocyclic compounds and uses thereof
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
WO2009039257A1 (en) 2007-09-19 2009-03-26 Albemarle Corporation Methods for production of 1,2,4-triazol-3-one
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
JP5600063B2 (en) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド Heteroaryl compounds and uses thereof
WO2009103032A1 (en) * 2008-02-15 2009-08-20 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
MY155639A (en) 2008-04-16 2015-11-13 Portola Pharm Inc 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
CA2728893C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
DK2361248T3 (en) 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
CA2736258C (en) 2008-09-23 2016-11-29 Rigel Pharmaceuticals, Inc. Tricyclic carbamate jak inhibitors
US8268851B2 (en) 2008-12-23 2012-09-18 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2010078369A2 (en) 2008-12-30 2010-07-08 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
PE20150621A1 (en) 2009-01-23 2015-05-07 Rigel Pharmaceuticals Inc DERIVATIVES OF 2,4-DIAMINE-PYRIMIDINE N2, N4-DISUSTITUTED AS JAK3 INHIBITORS
TW201040162A (en) 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
EP2438067B1 (en) 2009-06-05 2015-08-26 Boehringer Ingelheim International GmbH Spirolactams as cgrp-antagonists
MX337849B (en) 2009-07-28 2016-03-09 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway.
DE102010003599A1 (en) 2010-04-01 2011-10-06 Lisa Dräxlmaier GmbH Process for cable assembly and ready-made cable
WO2013010453A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Chemoking receptor antagonists
WO2013093940A1 (en) 2011-12-20 2013-06-27 Council Of Scientific & Industrial Research Nitrofurfuryl substituted phenyl linked piperidino-oxadiazoline conjugates as anti-tubercular agents and process for the preparation thereof
WO2013139717A1 (en) 2012-03-19 2013-09-26 Smardtv S.A. A cicam system for processing multiple programme transport streams

Also Published As

Publication number Publication date
US9556148B2 (en) 2017-01-31
CN105612154A (en) 2016-05-25
TWI562990B (en) 2016-12-21
PT3030561T (en) 2017-03-23
AR097282A1 (en) 2016-03-02
DK3030561T3 (en) 2017-03-27
WO2015019365A1 (en) 2015-02-12
EP3030561A1 (en) 2016-06-15
ES2618072T3 (en) 2017-06-20
EP3030561B1 (en) 2017-01-11
US20160176849A1 (en) 2016-06-23
KR20160030580A (en) 2016-03-18
TW201518290A (en) 2015-05-16
KR101665301B1 (en) 2016-10-11
HK1222386A1 (en) 2017-06-30
WO2015019365A8 (en) 2016-02-18
JP2016525071A (en) 2016-08-22
PL3030561T3 (en) 2017-08-31
HUE033448T2 (en) 2017-11-28
HRP20170277T1 (en) 2017-05-19

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12020500195A1 (en) Pyrimidinones as factor xia inhibitors
PH12014502615A1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
MX2011012353A (en) N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2, 3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS.
MX2016007371A (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimid in-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof.
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
MD4735B1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of Janus-related Kinases (JAK)
MX2013001970A (en) Pyrrolopyrimidine compounds and uses thereof.
MX2014002442A (en) Pyrrolopyrazine kinase inhibitors.
MX2013004298A (en) Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors.
GEP20227344B (en) Pyrimidine compound as jak kinase inhibitor
MX341577B (en) Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors.
PH12014502538A1 (en) Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods tehreof
NZ725001A (en) Tricyclic compound and jak inhibitor
IN2013MU02611A (en)
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
MY192305A (en) Bipyrazole derivatives as jak inhibitors
TN2010000471A1 (en) 2-6 diamino pyrimidin 5-yl carboxamides as syk or jak kinases inhibitors
TH131403B (en) New pyrimidine compounds As mTOR and PI3K inhibitors